摘要
目的:从炎症因子变化的角度探讨高血压病痰瘀互结的病因研究,观察高血压病患者血清炎症因子表达的差异,寻找与高血压病痰瘀互结证有关的炎症因子,并观察高血压病痰瘀互结患者经中药痰瘀同治干预后的降压疗效以及中医证候改善情况。
方法:收集自2007年4月19日至2010年8月31日中国中医科学院中医门诊部高血压病患者146例,其中痰瘀互结证患者116例,占79.46%,肝阳上亢患者30例,占20.55%。痰瘀互结组用痰瘀同治、解毒通络方(莱菔子、泽泻、川芎、水蛭等),肝阳上亢组用滋阴潜阳的天麻钩藤饮加减方(天麻、钩藤、生栀子、黄芩、桑寄生等)。治疗3个疗程(1个月为1疗程),采集治疗前后高血压病患者的四诊信息、、血压、心脏、颈动脉超声指标,监测肝、肾功能和血脂变化,应用3D-MRA光波检测全身各系统功能变化,分析中药干预后的降压有效率以及中医证候改善情况。并在治疗后随机选取痰瘀互结组、肝阳上亢组各6例患者的早晨空腹血样,用细胞因子抗体芯片检测血清40种炎症因子指标。分析炎症因子在两种证类治疗前后的差异,分析其相关性。
结果:
1.超声结果显示:①颈动脉检测异常:痰瘀互结组45例,占38.79%,肝阳上亢组8例,占26.67%。其异常主要表现为颈动脉粥样硬化、粥样硬化斑块及颈动脉狭窄;②心脏超声检测异常:痰瘀互结组44例,占37.93%,肝阳上亢组11例,占36.67%,主要表现为左室舒张功能降低及左室肥大。
2.抗体芯片检测结果显示:①痰瘀互结组治疗前后比较,TGF-betal(转化生长因子)和PDGF-BB(血小板衍化生长因子)治疗后均有明显降低,经统计学处理有显著差异(p<0.05):肝阳上亢组治疗前后比较,I-309(人T细胞分泌的种趋化因子)、IL-1 alpha、IL-16、IL-17、M-CSF(非分泌性巨噬细胞集落刺激因子)、MIG、IL-1(?)台疗后均有明显降低,经统计学处理有显著差异(p<0.05)。②中药干预过程中痰瘀互结组患者的N0含量水平有升高趋向。随着治疗时间的延长,痰瘀互结患者的TNF-a浓度含量有下降趋向,趋向于正常水平
3.经中药治疗后,降压总有效率为88.82%,证候改善总有效率为88.78%。患者停、减降压西药的比例达到42.36%,治疗过程中停服降压西药的共36人,占入组时服药人数的36.36%。
结论:
1.在高血压病痰瘀互结证患者中颈动脉内-中膜增厚、斑块形成等动脉粥样硬化性改变及心脏舒张功能减低、左心室肥大等病变,其发生率明显多于肝阳上亢证患者。
2.高血压病痰瘀互结组治疗前后在血清炎症因子的表达方面有差异。其中CRP, NO, TNF-α, TGF-beta 1和PDGF-BB与高血压病痰瘀互结证有相关性。因此,检测高血压病治疗前后这些细胞因子的水平变化对了解高血压病分级、评价临床疗效、推测预后具有重要的指导意义,为高血压病病因学研究提供生物学依据,对进一步探索高血压病的发病机理奠定了基础。
3.临床观察发现高血压病患者经过中药干预,降压总有效率为88.82%,证候改善总有效率为88.78%,部分患者可以停、减西药用量,因此痰瘀同治、解毒通络法治疗高血压病疗效确切,值得推广
Objective:
From the Angle of inflammatory factor change to Explore the Etiological of hypertension combination phlegm and blood stasis, observe hypertension patient serum inflammatory factor differences, Looking for hypertension combination phlegm and blood stasis related inflammatory factor, and observe the antihypertensive effects and Improve syndromes of TCM intervention.
Methods:
146 patients with hypertension were selected in The Clinic Of China Academy Of Chinese medical sciences from April 19, 2007 to August 31,2010, including 116 case of combination phlegm and blood stasis which was accounted 79.46% and 30 case of Yin deficiency and Yang hyperactivity which was accounted 20.55%. Clinical Application of Method Combined Synchronic Treating Phlegm and Blood Stasis on combination phlegm and blood stasis, and method nouring Yin and Checking exuberance of Yang on Yin deficiency and Yang hyperactivity. After three therapy course(one month as a course), through collecting the information from the TCM four diagnostic methods、Blood Pressure、values of cardiac ultrasound and Carotid Ultrasound, hepatic and renal function、Blood Lipid were measured before and after the treatment. The antihypertensive effects and Improve syndromes of TCM intervention are analyzed. The fasting blood samples were chosen, each group had 36 cases (combination phlegm and blood stasis、Yin deficiency and Yang hyperactivity、normal). To investigate the expression of inflammatory cytokines in patients by using an antibody chip.
Results:
1. Result of ultrasound:①the abnormal manifestation of Carotid Ultrasound:45 case(38.79%) of combination phlegm and blood stasis.8 case(26.67%) of Yin deficiency and Yang hyperactivity. They are mainly reflected in carotid atherosclerosis、Atherosclerotic Plaque and Carotid Artery Stenosis;②the abnormal manifestation of cardiac ultrasound:44 case(37.93) of combination phlegm and blood stasis,11 case(36.67%) of Yin deficiency and Yang hyperactivity. They are mainly reflected in Left Ventricular diastolic function and left ventricular hypertrophy.
2. Result of antibody chip:①The level of IL-11、GM-CSF and IL-1beta in combination phlegm and blood stasis was lower than that of normal group(p<0.05); The level of IL-10 and IL-15 in Yin deficiency and Yang hyperactivity was lower than that of normal group(p<0.05); The level of IL-11 in Yin deficiency and Yang hyperactivity was lower than that of combination phlegm and blood stasis (p<0.05).②There was a great difference in TGF-beta 1 and PDGF-BB between pre and post treatment(P<0 05) in combination phlegm and blood stasis; There was a great difference inⅠ-309、IL-1 alpha、IL-16、IL-17、M-CSF、MIG、IL-1 between pre and post treatment(P<0 05) in Yin deficiency and Yang hyperactivity.
3. After TCM Treatment, the total effective rate was 88.82% in reducing hypertension. The total effectiveness was 88.78% in improving the symptoms. Some 42.36% patients stop or reduce using the western medicine to reduce hypertension. Altogether has 36 people to stop the use of the western medicine to reduce hypertension accounted for 36.36%.
Conclusion:
1. The patients with combination phlegm and blood stasis are obviously more than the patients with Yin deficiency and Yang hyperactivity in some lesions, such as carotid intima-media thickening、atherosclerotic plaque、left ventricular diastolic function and left ventricular hypertrophy.
2. There was a great difference in inflammatory factors between pre and post treatment combination phlegm and blood stasis. The change of CRP, NO, TNF-α, TGF-beta 1 and PDGF-BB was closely positively correlated with combination phlegm and blood stasis.
3. This study discovered that after TCM Treatment the total effective rate was 88.82% in reducing hypertension and 88.78% in improving the symptoms. Partly patients stop or reduce using the western medicine to reduce hypertension. Therefore, the method that called synchronic treating phlegm and blood stasis has definite therapeutic effect.
引文
[1]韩学杰,丁毅,王丽颖,等.高血压病痰瘀互结与炎症因子相关的机制探讨中华中医药杂志[J],2010,25(3):361-364.
[2]刘英.抗体芯片的研究进展.现代免疫学[J],2006,26(3):251-254.
[3]严静,张召才,蔡国龙,虞意华,胡才宝,吴亮.抗体芯片分析炎性细胞因子在炎症脓毒症中的表达.中华急诊医学杂志[J].2006(9):830-833.
[4]张露,刘必成.抗体芯片技术在慢性肾脏病患者尿液细胞因子检测中的应用及意义探讨.2006.
[5]石丹,梁晓萍,梁海南,等.原发性高血压患者血清碱性成纤维细胞生长因子的临床研究(摘要)[J].中国循环杂志,2001,16(2)99.
[6]吴敏毓,刘恭植.医学免疫学.3版.合肥:中国科学技术大学出版社,1999:67-71
[7]Fichd sclleres S, Rosecnberer G.Diek H, er al. Elevated C reactive protein lecels and impaired endothelial vas oreactivity in patients with coronary artery disease.Circulation.2000.102:1000-1006
[8]Yasunri K, Maeda K, Nakamura M, et al. Oxidative stress in leukoytes is a possible link between blood pressure. blood glucose, and C-reactive protein.Hypertension.2002.39:777-780
[9]季宏,卞茸文,娄青林,顾刘保,仲肇舒。老年高血压患者颈动脉粥样硬化与血尿酸及相关炎症因子的关系。[J]实用老年医学2007,21:309-311.
[10]吴莹,戴秋艳,汪玮,郑兴。原发性高血压患者血清hs-CRP,sICAM-1与尿酸水平的相关性。[J]山东医药2009,49:34-36
[11]华军益,刘艳,王坤根。冠心病痰瘀辩证与血清炎症因子关系的临床研究[J].中西医结合,2008.37(3):112-114
[12]林桂永,阮威君.急性冠脉综合征痰瘀证与炎症关系的临床研究[J].2008.18(1) :10-14.
[13]Natham C. Points of control in inflammation. Nature,2002,420:846-853
[14]钱元良.中医对高血压病因病机的分析[J].世界健康杂志,2006,3(9):126-127.
[15]韩学杰,朱妍,陈捷,沈绍功.原发性高血压病痰瘀互结毒损心络中医证类的 的临床流行病学调查研究[J].中医基础医学杂志2008,14(6)453-455.
[16]沈绍功.沈绍功中医方略论北京:科学出版社,2001:236-238
[17]韩学杰.络活胶囊水煎剂治疗高血压病的临床与实验研究[J].中国中医急症,2002,8(1):4
[18]韩学杰,沈宁.毒损心络与高血压病[J].中医杂志,2005,46(2):155-156
[19]宋卫华.原发性高血压相关基因研究进展[J].中国份子心脏病学杂志,2005,5(2): 500.502
[20]张京春,陈可冀.关于美JNC-高血压指南的评述[J].中国中西医结合杂志,2003,,23(10):724-726
[21]韩学杰,沈绍功.痰瘀相关病因初探[J].中国中医基础医学杂志,1998.,4(8):44-46
[22]鞠大宏,韩学杰,谢雁鸣,等.高血压病从络论治探讨[J].中国中医基础医学杂志,2001,7(9):43-44
[23]吴国生.祛痰化瘀法治疗原发性高血压病32例[J].安徽中医学院学报,2006,25(4): 17-18
[24]王尚勇,周玉兰,王尚杰.醒脑清眩汤治疗高血压100例临床疗效观察[J].北京中医,2003,22(1):20-22
[25]游涛,徐淑静.止眩散治疗高血压50例[J].河南中医,2006,26(4):19
[26]史香玲,肖琳.中医药治疗舒张期高血压58例[J].河南中医,2003,,23(7):26
[27]袁成民.八物降压冲剂治疗原发性高血压的临床及实验研究[J].山东中医药大学学报,1999,,23(3):189-192
[28]严灿,张新春,邓中炎,等.心肌康对高血压性LVH逆转的临床作用观察及机理探讨[J].中国中医药科技,1995,,2(5):17
[29]成意伟,张罡.化瘀涤痰汤对高血压患者高血脂的影响[J].吉林中医药,2002,,22(1):44
[30]陈利群.健脾化痰活血祛瘀法对痰瘀互阻型原发性高血压病患者血脂和血液流变学的影响[J].河北中医,2005,27(2):93-85
[31]于向东,周文泉,崔玲,金龙,等.络活胶囊降压作用及对血浆肾上腺髓质素和组织因子途径抑制物的影响[J].中国中西医结合杂志,2003.,23(9):668-672
[32]金龙,周文泉.络活胶囊治疗痰瘀阻络型高血压病的临床研究[J].中国中西医结合杂志,2004,24(7):610-612
[33]梁颖瑜,潘毅,徐志伟,严灿,王剑.“调肝肾、祛痰瘀”治法早期干预队自发性高血压大鼠子鼠血压及VSMC钙离子浓度的影响[J]医学信息,2003,16(7):398-400
[34]卢焯明,潘毅,梁颖瑜,严灿,王剑.调肝肾、祛痰瘀治法提前干预队SHR血压及血管活性物质的影响[J].中国中医药信息杂志,2004,11(9):398-400
[35]唐咸玉,王剑,严灿,等.活血祛瘀法对高血压左心室肥厚大鼠心ras原癌基因表达的影响[J].中医研究,2001,14(1):14-16
[36]潘毅,吴丽丽,严灿,雷娓娓,等.活血祛瘀法对自发性高血压大鼠心肌线粒体膜的影响[J].广州中医药大学学报。2001,18(1):60-62
[37]罗智博,杨关林,李思琦,陈旭,论痰瘀同源[J].辽宁中医杂志2009,36(3):376-379.
[38]宋剑南.从生物化学角度看痰及痰瘀相关[J].中国中医基础医学杂志,2000,6(3):40-43.
[39]韩学杰,沈绍功.冠心病心绞痛痰瘀互结证的本质探讨[J].中国中医基础医学杂志,2002,8(10):53-54.
[40]韩学杰,张印生.冠心病痰瘀互结证的渊源和创新[J].中国医药学报,2004,19(10):623-625.
[41]Siwik DA, ColucciWS. Regulation ofmatrixmetallop roteinases by cytokines and reactive oxygen/nitrogen species in the myocardium [J]. Heart Fail Rev,2004。9: 43251.
[42]Graundy SM. In flammat ion、hypertension and the met abolic syndrome[J]. JAMA,2003,290(22):3000-3002。
[43]吕敏,师绿江,史平,等.中老年自然人群中高血压和亚临床颈动脉粥样硬化的关联研究[J].中华流行病学杂志.2004,25(10):841-4.
[44]田作军,刘磊,董亚贤,等.影响颈动脉斑块形成因素的临床分析[J].中华神经医学杂志,7(11):1168-73.
[45]中国高血压防治指南修订委员会.中国高血压防治指南(2005年修订版)[M].人民卫生出版社,2005,20.
[46]韩学杰,沈绍功.高血压病的中医研究现状及述评[J].中国中医基础医学杂志,,2005,11(4):320-322.
[47]匡调元.中国体质病理学[M].上海:上海科学普及出版社,1996.88-90.
[48]肖艳,邹旭,罗英.痰瘀兼夹型高血压病与动脉粥样硬化的关系[J].中华实用中西医杂志.2004,4(17):2246-2247.
[49]洪永敦,张智琳,李小兵,等.急性冠脉综合征痰瘀证候若干炎症因子的临床研究[J].新中医,2007,39(7):18-21.
[50]Antman KS,griffin JD,Elias A,et al.Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelo-suppression[J].N Engl J Med,1988,319:593-598.
[51]韩学杰,沈绍功.中医心病单元组合辨证分类法临证运用[J].中华中医药杂志,,2007,22(11):777-780.
[52]胡世云,冼绍祥,赵立诚,等.高血压病中医治法的临床研究进展[J].新中医,2003,35(1):69-71.